Benzinga's Top #PreMarket Gainers

shares climbed 15.56 percent to $9.24 in pre-market trading after the company reported reported positive top-line results from the Phase II study of FDX104 in Acneiform Rash.

shares rose 12.41 percent to $37.50 in pre-market trading after the company reported the early termination of Hart-Scott-Rodino waiting period.

shares rose 8.73 percent to $143.75 in pre-market trading after the company reported better-than-expected earnings for its fiscal fourth quarter.

shares surged 7.97 percent to $37.25 in pre-market trading after dropping 1.48 percent on Wednesday.

gained 6.90 percent to $18.59 in pre-market trading after the company reported stronger-than-expected results for the third quarter.